Retinalamin: nā ʻōlelo no ka hoʻohana ʻana, nā analogues a me nā loiloi, nā kumukūʻai ma nā lāʻau lapaʻau o Lūkia

Nā kumukūʻai ma nā lāʻau lapaʻau pūnaewele:

ʻO Retinalamin kahi lāʻau lapaʻau no ka hoʻohana ʻana i nā systemic i ka ophthalmology e hoʻomaikaʻi i ka uluna retinalation a me ka hoʻoliʻi ʻana o nā akeliila.

E hoʻokuʻu i ke ʻano a me ka ʻano

Loaʻa ʻo Retinalamin i ke ʻano o ka lyophilizate no ka hoʻomākaukau ʻana i kahi hopena no ka ʻae ʻana i ka ʻāpana intramuscular a parabulbar: ka nui porous a i ʻole nā ​​ʻāpana paha a i ʻole nā ​​melemele-keʻokeʻo (22 mg i kēlā me kēia i ka pahu wai 5 ml, i loko o kahi pā kihapai o 5 film PVC alumina / foil, i loko o ke kāʻei pepa 2 mau pā).

I loko o 1 pahu o ka lyophilisate i loaʻa:

• ʻO ka waiwai koʻikoʻi: retinalamin (kahi paʻakikī o ka hoʻopihapiha polypeptide wai-hoʻōla i ka wai o ka puaʻa) - 5 mg,
• Nā kumuwaiwai hou: glycine (stabilizer).

Nā hōʻailona no ka hoʻohana ʻana

• ʻO ka ʻōmua hāleʻa makana mua mua
• ʻO ke kumu retinopathy Diabetic,
• ʻO ka dystrophy retinal Central, ʻo ia hoʻi e pili ana i ka traumatic a me ka etiology inflammatory,
• Abiotrophy nui a me ka peripheral tapetoretinal retinal abiotrophy,
• ʻO kaʻu maʻi maʻi (ma ke ʻano o ka hoʻohui ʻana o ke ʻano lāʻau).

Nā Hoʻohui

• The dystrophy retinal Central of traumatic and inflammatory etiology, central and peripheral tapetoretinal abiotrophy - no nā keiki ma lalo o 1 makahiki.
• ʻO ka maʻi maʻi o ka maʻi, ka retinopathy maʻi maʻi, ka uku hoʻopihapiha o ka māka hoʻoneʻe mua - no nā keiki a me nā ʻōpio ma lalo o ka 18 makahiki o ka makahiki (ma muli o ka ʻike ʻole o ka palekana a me ka hana pono o ka lāʻau lapaʻau),
• Hypersensitivity i nā ʻāpana o ka huahana.

I ka wā hapai, ua contraindicated ka hoʻohana ʻana o Retinalamin (ʻaʻohe data e hōʻoia i ke palekana o ke komo ʻana).

Inā pono, hoʻohana i ka wā lactation e hoʻoholo i ka hoʻopau ʻana o ka umauma.

ʻLoe a me ke kākele

Hoʻonohonoho ʻia ka hoʻonā ʻana ʻo Retinalamin i hoʻomākaukau ʻia intramuscularly a i ʻole ka parabulbarno.

Palapala ʻia no nā pākeke:

• Abiotrophy kūloko a me nā peripheral abiotrophy, dystrophy retinal center o ka maʻi a me ka ʻatikala traumatic, retinopathy diabetic: intramuscularly a parabulbarly hoʻokahi lā i kahi lā he 5-10 mg, lōʻihi ka mālama ʻana - 5-10 mau lā, ka papa ʻelua e hiki ke kūpono inā pono ma hope o 3-6 mau mahina.
• ʻO ka glaucoma hāakaʻikau puka mua e koi ai: e lawe ʻia ana ka ʻōlelo intramuscular a parabulbar paha i ka manawa 1 i ka lā ma kahi o 5-10 mg, ʻo ka lōʻihi o ke kaupaona ʻana he 10 mau lā, hiki i ke kekona lua ke kuhikuhi ma hope o 3-6 mau mahina.
• ʻO ka maʻi Myopic: parabulbarno hoʻokahi manawa i ka lā ma kahi o 5 mg o ka papa, ʻoiʻa - 10 mau lā, ua ʻōlelo ʻia e hui pū me nā B vitamina a me nā lāʻau hoʻōkiʻi.

I ka mālama ʻana i ka abiotrophy waena me peripheral tapetoretinal, dystrophy retinal central of the inflammatory and traumatic etiology, ua hoʻonoho ʻia nā keiki a me nā ʻōpio i nā ʻōlelo intramuscular a parabulbar hoʻokahi i hoʻokahi lā i ka lā hoʻokahi, ma muli o ka makahiki:

• Mai ka makahiki 1 a i 5 mau makahiki - 2,5 mg i kēlā
• Mai 6 a 18 mau makahiki - 2.5-5 mg pākahi.

ʻO ka lōʻihi o ka mālamaʻana he 10 mau lā, inā pono, e hana hou ʻia ka papa ma hope o 3-6 mau mahina.

Ma mua o kahi o ka maʻi i ka hoʻoemi ʻia, ua hoʻoheheʻe ʻia ka lyophilisate me 1-2 ml o kahi hopena o ka sodium chloride 0.9% (no nā keiki a me nā pākeke), ka wai no ka hoʻonā a i ʻole he 0.5% hopena o procaine, a i ʻole novocaine (ʻo nā pakeke wale nō). I mea e pale ʻole ai i ka ʻaihue, hāmama ʻia ka alakaʻi ʻana i ka wailele i ka wā e hoʻopuka ana i ka lapalapa i ka paia o ka vial.

Nā ʻōlelo kikoʻī

ʻAʻole hiki ke mālama ʻia i ka hoʻonā i hoʻomākaukau ʻia; pono e hoʻokaʻawale ʻia ka lyophilisate me kahi hāpū koke ma mua o ka paʻi ʻana.

ʻAʻohe hiʻohiʻona o ka hana a Retinalamin i ka hopena mua a i ʻole ma ka hopena o ka papa.

Hoʻohana wale ʻia ka mea hoʻonā e like me ka kuhikuhi a ke kauka hele mai.

Inā hōʻiho ʻoe i ka maʻi kaukani hou, ʻaʻole hiki iā ʻoe ke komo i kahi helu ʻelua, e pono ke hoʻokele ʻia e like me ka papa kuhikuhi no ka hoʻohana ʻana o ka lāʻau lapaʻau.

ʻAʻole ʻōlelo ʻia ka hoʻonā Retinalamin e hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe.

ʻAʻole hoʻopilikia ka mea hana i ka hiki ke hoʻokele i nā mīkini paʻakikī, me nā kaʻa.

Nā hopena hopena

Hoʻomaopopo ka ʻōlelo aʻo i ka hiki ke hoʻomohala i nā hopena ʻaoʻao aʻe i ka wā i kuhikuhi ai iā Retinalamin:

• Allergic hopena ma kahi hihia o ka hypersensitivity pilikino i nā mea o ka lāʻau.

Nā Hoʻohui

Hoʻopili ʻia ʻo Retinalamin i kēia mau helu:

• ʻO ka ʻōpū a me ka manawa ʻai (ʻo ka ʻike palekana no kēia pūʻulu o nā maʻi i aʻo ʻia),
• He makahiki a hiki i ka 1 makahiki (tapetoretinal abiotrophy (waena a me peripheral), dystrophy retinal center o ka maʻi a me ka ʻano traumatic) a a hiki i 18 mau makahiki (ka hoʻopuka hoʻopuka piha ʻana i ka pualikau maʻamau, retinopathy diabetic, maʻi myopona - ka ʻike palekana no kēia ʻōpio o nā mea maʻi ʻaʻole i aʻo ʻia).
• Hypersensitivity i ka lāʻau lapaʻau.

ʻAʻohe huaʻōlelo i ka pili me nā lāʻau lapaʻau / lāʻau ʻē aʻe.

Ke keu

ʻAʻole hoʻolako i ka ʻike helu overdose. ʻAʻole kākau ʻia nā hihia o ka overdose i kēia manawa.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

ʻO Retinalamin i hōʻike ʻia e kahi lyophilisate, i hana ʻia i ke ʻano o kahi kāla o ka poni o ke keʻokeʻo a i ʻole ʻulaʻula paha, pono ia no ka hoʻomākaukau ʻana i kahi hopena terapeutic. ʻO ke alanui o ka hoʻokele waiwai o ka lālani intramuscularly a parabulbar. Hoʻokahi i hoʻokahi pahu me 2 a 5 mauʻaina paha. Hāʻawi kahi hopena therapeutic paʻa i ka hoʻopili ʻana i nā mea i hōʻiliʻili ʻia i ka pūnaehana kemu o Retinalamin:

pipi waila polypeptides (5 mg)

Ka hana lāʻau lapaʻau

He mea hōʻoluʻolu hoʻoneʻeneʻo ia i mea e loaʻa ai ka hopena leʻaleʻa i nā cell retinal a me nā photoreceptors, hoʻomaikaʻi i ka hana pono o nā kinipona kinipōpō, a hoʻihoʻi i ka hoʻāʻo ʻana i nā mea kiko o ka ʻike. Ma lalo o ka mana o nā hipa retinal polypeptides, hiki ke hoʻihoʻi koke ʻia ka ikaika o ka vascular, hiki ke hoʻemi ʻia ka nui o ke ʻano o ka maʻi ʻaole, a hiki ke loli hou ʻia nā hana hou.

ʻAʻole hiki i kahi loiloi pharmacokinetic piha o nā hana ikaika i hiki ʻole. I waena o nā hiʻohiʻona kūpono o ka mālama conservative me Retinalamine, pono e ʻoki i kēlā i nā hana i kahi pākuʻina o ka polypeptide palupalu a ka wai me ke kaumaha o ka molekula a hiki i ka 10,000:

• hoʻomaikaʻi i ka metabolism o nā loko o nā maka,
• hoʻōla i ka syntacellular protein synthesis,
• hoʻōla i ka hana o nā membrane o nā cell retinal,
• kūleʻa i ka hoʻoulu ʻana i nā ʻaihā, nā hana dystrophic o nā wahī,
• hoʻoponopono i ke kaʻina lipid oxidation,
• hoʻolako i ka retina i nā huaora i koi ʻia,
• hoʻonui i ka acuity ʻike ma hope o ka papa mua,
• hoʻihoʻi i nā kaʻina kumu.

Hoʻohui nūhou

ʻAʻole hiki i nā mea hoʻokūkū koi ke koi i ka hoʻopili ʻana i kekahi mau loina i hoʻokahi pahu i hoʻokahi manawa. Mai nā hana like ʻole, ua nawaliwali ka hopena therapeutic o kēia lāʻau lapaʻau, ʻaʻole ʻae ʻia nā hopena ʻaoʻao. Ma nā ʻōlelo ʻē aʻe, ʻaʻole i hōʻike ʻia nā mea hoʻopiʻi retinalamin e hoʻomaʻamaʻa ʻia i nā ʻōlelo kikoʻī.

Nā hopena ʻaoʻao a me ka overdose

ʻAʻohe hopena hopena i hōʻike ʻia e nā pediatricians a me nā lāʻau lapaʻau, ʻaʻole hoʻi i kākau ʻia e nā ophthalmologists. ʻO kahi meaʻokoʻa aʻe ka hoʻonui pinepine ʻana o ke kino i nā mea ikaika mai ke kumu o Retinalamin. I ka hopena, aia nā hopena alaka i ke kūleʻa i waena ma ke ʻano kūlohelohe, koi i ka hōʻoki ʻana i ka lāʻau a i ʻole kāna hoʻololi me kahi mea hoʻohālike.

Nā ʻōlelo a ke kūʻai a me ka waiho ʻana

Hiki ke kūʻai ʻia ʻo Retinalamin ma kahi lāʻau lapaʻau me ka ʻole ke kumukūʻai, akā hiki ke hoʻohana ʻia e like me ka kauka ʻana. E mālama i ka pauka i loko o nā pahu i kahi maloʻo a ʻeleʻele. Hōʻike e nānā i nā lā i hala. Inā pau ka lāʻau, hoʻopau koke i kekahi, kūʻai i kahi lāʻau hou e hana ai i nā inikini intramuscular.

Pharmacodynamics a me ka pharmacokinetics

Ke loaʻa nei ka lāʻau lapaʻau ka paʻakikī o ka hoʻohuihui wai nā ʻōnaehana protein. Nā hana hana i ka hana ʻo ka hoʻomaikaʻi ʻana i ka metabolism o ka kiko o ka maka a hoʻomaʻamaʻa i ka hana o nā membrane cell. He pono ka hopena o ka lāʻau lapaʻau ma hoʻonani protein, a hoʻoponopono pū i nā kaʻina hana ʻōmaʻomaʻo momona, pili i ka maʻamau o ke kaʻina o ka ikehu.

ʻAʻole hiki ke mālama i kahi loiloi pharmacokinetic, no ka mea ka mea hana i ka hoʻopiha piha ʻana i nā hoʻopina polypeptide.

No ke aha i kuhikuhi ʻia ai

ʻO Retinalamin kahi bioregulator peptide i hoʻolālā ʻia no ka hoʻoponopono hou ʻana i ka aea. ʻO ka pahuhopu mea nui ka paʻakikī o nā hoʻopalike manuahi retinal polypeptide. Loaʻa ka lāʻau lapaʻau i ke ʻano o kahi lyophilisate (pauka no ka hoʻonā). Hoʻohana ʻia ia intramuscularly a i ʻole i ka orbit (parabulbar).

Hoʻokumu ʻo Retinalamin i nā mea pili i nā waihona retina a me nā photoreceptor. Me nā loli dystrophic, kōkua ka lāʻau lapaʻau e hoʻoikaika i ka pilina ma waena o nā ʻāina waho o nā photoreceptors a me ka puaʻa epithelium, e hoʻihoʻi ana i ka ʻike ʻoluʻolu o ka retina. Eia kekahi, hoʻihoʻi ʻo Retinalamin i ka maikaʻi o nā kīʻaha koko a hoʻomaikaʻi i ke ola ponoʻī ponoʻī o ka retina i loko o kāna mau ʻōnaehana like ʻole.

Hoʻokuʻu ʻia ka lāʻau lapaʻau i ke ʻano o kahi keʻokeʻo keʻokeʻo a iʻa polū paha. I loko o hoʻokahi pahu mea ʻelua kīpē o 5 mauʻaila. Kahi kūloko he 5 mg o ka polypeptide wai-hoʻōla i loko o kahi retinalle, a me ka 17 mg o ka glycine.

Hoʻokuʻu ʻia ka mea hana e ka hui ʻo Lūkia "Geropharm". ʻO ke kumu kūʻai o kahi pākahi mai 3500 a 4500 mau rubles, akā hoʻokahi, ma ke ʻano he kānāwai, ua lawa nō no ka papa o ka mālama ʻana.

Nā hōʻailona a me nā contraindications

Ua manaʻo ʻia ʻo Retinalamin ka hōʻailona nui no ke koho ʻana i ka dystrophy retinal. ʻO kahi mea ophthalmologist wale nō e hiki ke hoʻoholo i ka ʻōlelo aʻo o ka koho ʻana i ka lāʻau lapaʻau ma muli o nā kumu kumu o ka dystrophy a me nā pathologies pili.

Nā hōʻailona no ka hoʻohana ʻana o Retinalamin i nā ophthalmologists:

1. Hoʻokomo ʻia i ka retinopathy Diabetic. Me ka maʻi maʻamau, e pinepine pinepine ʻia nā ʻōkuhi o ka maka. Ma waho o ka mālama ʻana, hiki i ka retinopathy maʻi maʻi ke alakaʻi i ka makapō. Ke holomua nei ka maʻi, akā mau ka neʻe ʻana: lilo nā kīʻaha koko i mea palupalu, ʻike ʻia nā ʻūhū o nā retinal. I kēia hihia, pilikia nā hana ʻike, neʻe ʻia nā scars e hoʻopaʻa i ka retina, e hoʻokau ana i kahi detasment.
2. Abiotrophy waena a me peripheral. ʻIke pinepine ʻia kēia maʻi a ʻike ʻia e ka wā hōʻino ʻia e nā photoreceptors. ʻO ka pinepine, ʻo ke kumu o ka abiotrophy he predisposition hoʻoilina. Ua nalowale ka ʻike ʻana, ʻoi ʻia ka ʻike o ka ʻike maka. Me ka abiotrophy, hiki ke hoʻopau piha loa i ka hihiʻo.
3. Post-traumatic and inflammatory central retinal dystrophy. ʻO ke kumu o ke kūlana loaʻa ʻole nā ​​mea pale i ka ʻōnaehana vascular o ka eyeball. Me ka dystrophy retinal, luku ʻia nā photoreceptors, nāna ke kuleana no ka ʻike ʻana i nā kala a me ka ʻike mamao. I ka wā mua, ua like ka maʻi asymptomatic, akā i ka wā e hiki mai ana he wā e hōʻemi ai i ka ʻike kiko, peripheral vision a me ka orientation i ka pōʻeleʻele.
4. ʻO ka glaucoma hoʻokaʻawale mua i ka makana. ʻO kēia kahi paʻakikī o nā alaʻala e hoʻopiʻi i ka piʻi o ka intraocular pressure ma muli o ka hoʻopololei pono ʻole ʻana o ka maluhia o ka maka me ke ʻano maʻamau o ke kihi o ke keʻena anterior o ka maka. Hōʻike pinepine ʻia ke kihi glaucoma i nā manawa pinepine. I ka wā mua, hoʻomau ka maʻi ʻole me nā hōʻailona ʻole. ʻAʻole paʻa i nā kumu kumu.

Hoʻomaʻamaʻa ʻia ka lāʻau retinalamine no nā maʻi ʻē aʻe o ka retina. ʻAʻole pono ka lāʻau i nā cataracts a me ka retinitis pigmentosa. E pili ana i nā maʻi āpana i ka ʻike ʻana o ka pilikino i nā mea like, ka hapai a me ka lactation. ʻO ka maʻamau, ʻaeʻole ka poʻe maʻi i ka lāʻau lapaʻau, akā i kekahi mau hihia, hiki mai nā maʻi like ʻole. Hoʻomaopopo ka hopena ʻaoʻao like me ka kāwili ʻana o kēlā me kēia mahele.